Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Blinded, Two-part, Phase II Trial to Evaluate the Safety and Immunogenicity of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) in Adults 18 Years and Older

Next Previous
X
Search
Trial Profile

A Randomized, Blinded, Two-part, Phase II Trial to Evaluate the Safety and Immunogenicity of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) in Adults 18 Years and Older

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Recombinant two component COVID 19 vaccine Jiangsu Rec Biotechnology (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; First in man; Pharmacodynamics; Therapeutic Use
  • Acronyms ReCOV
  • Sponsors Jiangsu Rec-Biotechnology

    • Most Recent Events

    • 16 Dec 2023 Results from this and other study assessing Safety and Immunogenicity, published in the Infectious Diseases and Therapy
    • 24 Apr 2023 Status changed from active, no longer recruiting to completed.
    • 04 Oct 2022 According to clinicalytials.gov record, Protocol of this study has been amended, there is change in phase II/III to Phase II, Patient number has been decreased to 947 from 20301, Primary endpoint was changed as well, Interventional Study Model, Arms, Inclusion and Exclusion criteria of the trial were changed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top